Barclays has told a London court that it rightfully refused to transfer approximately $13 million back to a sanctioned shipping company at Reed Smith LLP's request after a collapsed tanker deal, arguing that it declined so it could avoid violating sanctions.

A barrister who advised the Post Office on its past prosecutions has denied "turning a blind eye" by not investigating why an expert witness whose evidence was used to convict innocent people misled the courts, as he appeared before an inquiry on Wednesday.

Britain's highest court ruled Wednesday that South Africa has sovereign immunity against a salvage repayment claim from a company that recovered around $43 million worth of silver bullion from a cargo ship sunk during the Second World War.

A businessman's family took its fight with a UAE bank to Britain's highest court Tuesday over an alleged £19 million ($24 million) debt, arguing that the lender should not be allowed to collect on debts he says are illegitimate and a result of fraud.

Employees of the U.K.'s official statistics department are refusing from Wednesday to return to the office for two days a week in what might mark out a new battleground in industrial relations.

Reviews are vital for online shopping, but fake posts have become a cottage industry for fraudsters. However, websites are fighting back, often using the same artificial intelligence tools deployed by scammers.

Kevin Spacey successfully bid to overturn a default judgment against him at a London court on Tuesday — but the actor now faces a trial to fight off a man's £457,000 ($574,000) sexual assault claim.

The Court of Appeal will hear a judge's challenge to a secretive part of the judicial appointment process that critics argue hinders efforts to diversify the bench, the GMB Union said on Tuesday.

Proposals to radically expand access for members of the public to court documents risk disproportionately burdening court staff and lawyers with work and could lead to additional costs, legal experts have said.

A biosimilars specialist and its licensing partner have challenged the validity of Regeneron's U.K. eye medicine patents amid their plans to market an alternative version, telling a London court that the medicine lacks inventiveness and is not worthy of protection.